See highlights from the Global Science Summit

Current Pipeline
FASTFunded
di-siRNA

MGH

Mass General Hospital (MGH) is exploring an investigational di-siRNA (divalent small interfering RNA) approach to paternal gene activation as a potential treatment for Angelman syndrome.

Discovery & DevPre-clinicalPhase 1Phase 2Phase 3To Patients

About the Program

A therapeutic approach using small pieces of RNA, called divalent small interfering-RNA (di-siRNA) that are aimed to bind to the UBE3A-ATS and prevent the silencing of the paternal copy of the UBE3A gene, enabling UBE3A protein to be made.

Collaborators
Mark Deehan

Program News

Career Development Awards Expand the Next Wave of Angelman Syndrome Research

Read More

What are you looking for?

Find information on Angelman syndrome, research, clinical trials, resources, and ways to get involved.